80%Confidence
0Views
FDASource
2026-03-05Date
Summary
Amerisource's oxycodone packaging defects create both regulatory and security concerns for controlled substance distribution. This could lead to increased DEA scrutiny and potential supply chain disruptions for pain management medications.
Actionable: Assess Amerisource's quality control systems and consider potential impacts on their pharmaceutical distribution business segment.
AI Confidence: 80%
Data Points
firmAmerisource Health Services LLC
classificationClass II
statusOngoing
distributionNationwide in the USA
productOxycodone Hydrochloride Tablets, USP (CII), 5 mg, 100-Count (10 x 10) blister cards per carton, Rx Only, The drug product contained in this package
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now